個股熱度排行 | 11月9日港股盤前
根據uSMART輿情監測數據,從8日晚間到9日港股盤前時間段,市場關注指數最高的2只股票是比亞迪股份、再鼎醫藥-B。
11月9日—港股關注排行TOP2

比亞迪股份

關注度第一爲比亞迪股份,該股上個交易日收盤下跌1.21%,報於196.10港元。近5個交易日累計上漲6.81%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:
乘聯會崔東樹:10月新能源乘用車市場創歷史新高 比亞迪夯實領先地位
比亞迪、吉利領銜 10月自主品牌零售份額、新能源滲透率雙雙超五成
再鼎醫藥-B

關注度第二爲再鼎醫藥-B,該股上個交易日收盤下跌2.18%,報於24.65港元。近5個交易日累計上漲29.74%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:
再鼎醫藥-B週五起股份簡稱不再加上標記「B」
再鼎醫藥-B:中英文股份簡稱將不再加上標記"B"
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.